Inventor · disambiguated record
Gustavo Droguett
Also filed as: DROGUETT GUSTAVO
13 granted patents·11 pending applications·36 citations·filing 2014–2025
89Inventor score
Top patents by PatentIndex Score
24 records- 0191US10457960B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2015·Granted Oct 29, 2019·5 cites·53 claims
- 0291US10106820B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2015·Granted Oct 23, 2018·6 cites·43 claims
- 0391US9902971B2Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generationREGENERON PHARMA·Filed 2015·Granted Feb 27, 2018·5 cites·41 claims
- 0490US10793874B2Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 0589US10781453B2Non-human animals having a hexanucleotide repeat expansion in a C9ORF72 locusREGENERON PHARMA·Filed 2017·Granted Sep 22, 2020·6 cites·48 claims
- 0686US2024352489A1Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0785US10294494B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2017·Granted May 21, 2019·2 cites·43 claims
- 0882US12060571B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2019·Granted Aug 13, 2024·1 cites·49 claims
- 0982US10023916B2Markers of tumor cell response to anti-cancer therapyREGENERON PHARMA·Filed 2014·Granted Jul 17, 2018·5 cites·3 claims
- 1080US2023332185A1Methods and compositions for targeted genetic modification using paired guide rnasREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1179US11697828B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2019·Granted Jul 11, 2023·1 cites·33 claims
- 1277US2025280805A1Methods for producing antigen-binding proteins against foreign antigensREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1374US12342801B2Methods for producing antigen-binding proteins against foreign antigensREGENERON PHARMA·Filed 2021·Granted Jul 1, 2025·0 cites·20 claims
- 1471US10893666B2Production of fertile XY female animals by silencing of genes on the Y chromosomeREGENERON PHARMA·Filed 2016·Granted Jan 19, 2021·1 cites·26 claims
- 1571US2023337645A1Nuclease-mediated repeat expansionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1670US2021024953A1Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1766US12041918B2Production of fertile XY female animals by silencing of genes on the Y chromosomeREGENERON PHARMA·Filed 2020·Granted Jul 23, 2024·0 cites·18 claims
- 1863US11690362B2Nuclease-mediated repeat expansionREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted Jul 4, 2023·0 cites·47 claims
- 1963US2016060657A1Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 2060US2020370054A1Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locusREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2159US2023114649A1HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2259US2017332610A1Methods for breaking immunological tolerance using multiple guide rnasREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 2358US2016046960A1Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 2450US2018291468A1Markers of tumor cell response to anti-cancer therapyREGENERON PHARMA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gustavo Droguett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →